These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29376912)

  • 1.
    Tam P; Gee K; Piechocinski M; Macreadie I
    J Fungi (Basel); 2015 Sep; 1(2):277-292. PubMed ID: 29376912
    [No Abstract]   [Full Text] [Related]  

  • 2. Discriminative power of fatty acid methyl ester (FAME) analysis using the microbial identification system (MIS) for Candida (Torulopsis) glabrata and Saccharomyces cerevisiae.
    Peltroche-Llacsahuanga H; Schmidt S; Lütticken R; Haase G
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):213-21. PubMed ID: 11146246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida glabrata: a deadly companion?
    Bolotin-Fukuhara M; Fairhead C
    Yeast; 2014 Aug; 31(8):279-88. PubMed ID: 24861573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata.
    Vu BG; Thomas GH; Moye-Rowley WS
    mBio; 2019 Jun; 10(3):. PubMed ID: 31186322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Efflux Pumps and Fatty Acid Activator One Genes in Azole Resistant Candida Glabrata Isolated From Immunocompromised Patients.
    Farahyar S; Zaini F; Kordbacheh P; Rezaie S; Falahati M; Safara M; Raoofian R; Hatami K; Mohebbi M; Heidari M
    Acta Med Iran; 2016 Jul; 54(7):458-64. PubMed ID: 27424018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis.
    Miranda-Cadena K; Marcos-Arias C; Mateo E; Aguirre JM; Quindós G; Eraso E
    Arch Oral Biol; 2018 Nov; 95():100-107. PubMed ID: 30096698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
    Vermitsky JP; Earhart KD; Smith WL; Homayouni R; Edlind TD; Rogers PD
    Mol Microbiol; 2006 Aug; 61(3):704-22. PubMed ID: 16803598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomes shed light on the secret life of Candida glabrata: not so asexual, not so commensal.
    Gabaldón T; Fairhead C
    Curr Genet; 2019 Feb; 65(1):93-98. PubMed ID: 30027485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A system for gene cloning and manipulation in the yeast Candida glabrata.
    Zhou P; Szczypka MS; Young R; Thiele DJ
    Gene; 1994 May; 142(1):135-40. PubMed ID: 8181748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.
    Tantivitayakul P; Lapirattanakul J; Kaypetch R; Muadcheingka T
    J Glob Antimicrob Resist; 2019 Jun; 17():221-226. PubMed ID: 30658200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
    Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
    AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candida glabrata: an emerging oral opportunistic pathogen.
    Li L; Redding S; Dongari-Bagtzoglou A
    J Dent Res; 2007 Mar; 86(3):204-15. PubMed ID: 17314251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents.
    Redondo-Lopez V; Lynch M; Schmitt C; Cook R; Sobel JD
    Obstet Gynecol; 1990 Oct; 76(4):651-5. PubMed ID: 2216197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ergosterol synthesis and storage in the yeast Torulopsis lipofera.
    BRADY BL; STEVENS R
    Arch Biochem Biophys; 1959 Jun; 82(2):479-82. PubMed ID: 13661977
    [No Abstract]   [Full Text] [Related]  

  • 17. Ergosterol synthesis and storage in the yeast Torulopsis lipofera.
    SCHUYTEMA CG; LATA GF
    Arch Biochem Biophys; 1958 May; 75(1):40-5. PubMed ID: 13534685
    [No Abstract]   [Full Text] [Related]  

  • 18. A method developed for the study of yeast production with Torulopsis utilis.
    THAYSEN AC; MORRIS M
    Antonie Van Leeuwenhoek; 1947; 12(1-4):204-14. PubMed ID: 20255088
    [No Abstract]   [Full Text] [Related]  

  • 19. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
    Keniya MV; Ruma YN; Tyndall JDA; Monk BC
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.